Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines

Provides an update on the epidemiology of pneumococcal disease since the introduction of Prevnar® (Wyeth Pharmaceuticals), as well as information regarding a newly authorised conjugate vaccine against pneumococcal disease, Synflorix™ (GlaxoSmithKline Inc.). Also updates the conjugate pneumococcal vaccination schedules used in Canada and provides recommendations on the use of new pneumococcal vaccines.